Evolution in Oncology - Caris Life Sciences and ConcertAI

Caris Life Sciences Executive Vice President, Chief Medical Officer George Sledge, and ConcertAI CEO discuss how high-depth and population-scale clinico-genomic datasets will impact translational sciences, early-phase clinical trials, and clinical lifecycle management.

Learn more:
https://www.carislifesciences.com/pro...

0:00 - Intro
1:16 - More data is better
4:21 - Whole exome sequencing in large patient populations
6:02 - Analyzing the complexity of tumor biology
7:37 - Precision oncology approach
10:26 - Understanding the dynamic evolution of cancer
13:29 - The molecular revolution has begun
15:21 - Molecular signatures
18:53 - AI signatures: prediction of brain metastasis
22:14 - New drug indications and life cycle planning
25:59 - Caris Assure: blood-based profiling
30:02 - New opportunities for cancer prevention and precision medicine
33:13 - Caris and ConcertAI working together
34:03 - Question 1: Advice for assessing resistance mechanisms?
36:43 - Question 2: How long is a tumor’s molecular data relevant (tumor evolution)?
39:05 - Closing comments